Health News

New Hope in Fighting XDR–TB

[Posted 2/27/09] Research by Albert Einstein College of Medicine and National Institute of Allergy and Infectious Diseases provides new hope in treating extensively drug–resistant tuberculosis (XDR–TB).

A combination of two FDA–approved drugs (clavulanate and meropenem) has been shown to be effective not only in treating TB, but also in inhibiting the growth of 13 XDR–TB strains.

The study was published in the February 27 issue of Science.

Related Links:

Science Abstract

Healthfinder News Article